Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Total Current Liabilities

All obligations due within one year.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total current liabilities falls 14.3% from a year ago

Total current liabilities stood at $74.99M at the end of Q2 FY2026, down 14.3% from a year earlier and up 19.7% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.

Context

  • Total current liabilities amounted to 4.6% of total assets at the end of Q2 FY2026, down 3.2 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -14.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$74.99M+19.7% QoQ
Last fiscal yearDec 2025
$83.21M+22.8% YoY
Year agoJun 2025
$87.54M-14.3% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.3%——
1 year+22.8%——
3-year CAGR+5.3%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
83.21M USD
Year-over-year change
+22.8%
4-year CAGR
-2.6%

Total Current Liabilities vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's Jun 2026 total current liabilities of $74.99M is the 3rd highest of the 5 companies compared; the peer median is $93.47M.
  • Its year-over-year change of -14.3% is the 3rd highest of 5, against a peer median of -6.6%.
  • Total current liabilities amounts to 4.6% of total assets for KYMR, versus a peer median of 10.3%.
KYMR Competitors Peer median
Total Current Liabilities for KYMR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$130.74M +58.8%+7.0%10.9%
ARVNArvinas, Inc.Mar 2026$115.9M -45.8%-21.5%17.9%
KYMRKymera Therapeutics, Inc.Jun 2026$74.99M -14.3%+5.3%4.6%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$71.04M +20.0%+35.9%9.6%
CCCCC4 Therapeutics, Inc.Mar 2026$27.25M -33.2%-9.5%8.3%
Peer median (excluding KYMR) $93.47M-6.6%-1.3%10.3%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents47.98M68.4M109.97M120.26M357.01M
Short-term Investments394.44M338.77M264.92M368.49M491.27M
Net Receivables135K2.54M18.76M947K0
Inventory00000
Other Current Assets09.71M11.67M20.58M22.94M
Total Current Assets451.27M419.42M405.32M510.27M871.21M
Property, Plant & Equipment (Net)21.31M22.24M101.08M97.86M85.53M
Goodwill00000
Intangible Assets00000
Long-term Investments125.19M152.33M61.43M362.16M776.96M
Tax Assets00000
Other Non-current Assets8.14M9.15M7.93M7.74M9.11M
Total Non-current Assets154.63M183.72M170.44M467.77M871.6M
Total Assets605.91M603.13M575.76M978.04M1.74B
Account Payables4.01M4.34M7.08M5.99M4.01M
Short-term Debt000013.76M
Tax Payables00000
Deferred Revenue61.74M35.26M37.88M13.58M22.93M
Other Current Liabilities228K303K23.16M223K24.21M
Total Current Liabilities92.54M71.34M85.69M67.77M83.21M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)39.3M28M16.77M011.44M
Other Non-current Liabilities66K248K000
Total Non-current Liabilities53.73M41.64M95.1M74.65M79.94M
Total Liabilities146.27M112.98M180.79M142.42M163.15M
Common Stock5K6K6K7K8K
Retained Earnings(228.98M)(383.79M)(530.75M)(754.61M)(1.07B)
Accumulated OCI(660K)(4.95M)(552K)(1.49M)1.8M
Other Stockholders Equity00000
Minority Interest00000
Total Equity459.64M490.15M394.97M835.62M1.58B
Total Debt17.96M17.34M84.67M87.76M82.25M
Net Debt(30.01M)(51.06M)(25.29M)(32.5M)(274.76M)

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.